Non-alcoholic steatohepatitis is a severe liver disease which affects 6-8% of adults in western industrialised nations and is on the rise around the globe.

Inventiva is developing lanifibranor for the treatment of NASH to address all the key features of this disease: inflammation, steatosis, ballooning, and more importantly fibrosis.

We are currently investigating lanifibranor for the treatment of NASH in NATIVE, a phase IIb clinical trial, with results expected in the first half of 2020.

Lanifibranor completed a phase IIb study. After only 6 months of treatment, lanifibranor achieved statistically significance in both regulatory endpoints required by FDA and EMA: resolution of NASH without worsening of fibrosis and reduction in fibrosis without worsening of NASH. These results, in addition to an excellent safety profile, clearly differentiate lanifibranor from any other treatment in development for NASH. For more details of the headline results see the results presentation.

MPS is a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells.

Inventiva is developing odiparcil, an orally-available small molecule designed to modify how GAGs are synthesized.

In the recently completed iMProveS phase IIa study, odiparcil confirmed its favourable safety profile and demonstrated efficacy in adult MPS VI patients, especially in tissues types not reached by standard of care.

Lanifibranor
Phase IIb trial in NASH, enrollment completed

Odiparcil
Phase IIa in adult MPSVI patients, completed